PDF

Project 2 - Liver Angiotensinogen Promotes Renal Scarring

Project Leader: Iekuni Ichikawa, M.D., Ph.D.

Co-Investigator: Ji Ma, M.D., Ph.D.

Consultant: Taiji Matsusaka, M.D., Ph.D.

Category
Page
Record History
Added on January 23, 2012 at 1:10 PM by Brand, Dominique
Modified on January 23, 2012 at 1:26 PM by Brand, Dominique
Shared with (contributions)
PCEN: Projects Master

Inhibition of angiotensin II (AII) is the only therapy currently known to have some effect in chronic kidney disease (CKD).  However, current ways of inhibiting only attenuate, but do not halt, progression.  Our studies aim to find new ways to inhibit AII in the kidney by determining why kidney AII is activated in CKD.  We will use mice with absence of AII precursor in the liver or kidney, and mice that cannot reabsorb the precursor molecule because of a tubular defect, to determine why AII is increased and how it can be blocked.